Progress in Precision Medicine for GIST Patients
These new data were presented by Dr. Sebastian Bauer and Dr. Breelyn A. Wilky during the 2023 January ASCO Plenary Series from the INTRIGUE Efficacy Results of ctDNA Analysis for GIST Patients.
These new data were presented by Dr. Sebastian Bauer and Dr. Breelyn A. Wilky during the 2023 January ASCO Plenary Series from the INTRIGUE Efficacy Results of ctDNA Analysis for GIST Patients.
Recent articles have shed light on an issue of concern about counterfeits for patients who take imatinib myselate as part of their treatment for GIST.
Dr. Yoon-Koo Kang of the Asan Medical Center, Seoul, Korea, discusses the results of his team's study on the effect of L-carnitine in muscle cramps in GIST patients who are on imatinib.
In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.
The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.
Patient-reported outcomes is a buzz-phase that we hear a lot these days. At the Life Raft Group, I was recently in a meeting where we were discussing patient-reported outcomes, the LRG registry and patient-powered [...]
A significant finding from a newly published study in JAMA Oncology, indicates that nearly one-fourth of GIST patients with advanced disease initially treated with imatinib will survive for ten years or more. The study, [...]
A recent study published in Oncotarget, discussed the potential role of the kinase, ABL1 as a potential impediment to anti-tumor processes in GIST treated with imatinib mesylate. The Life Raft Group’s Research Team member, [...]
On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]
A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the [...]